References
1. Gilling PJ et al. Five-year outcomes for Aquablation therapy compared to TURP: results from a double-blind, randomized trial in men with LUTS due to BPH. Can J Urol. 2022;29(1):10960-10968.
2. Bhojani et al. Aquablation therapy in large prostates (80-150 mL) for lower urinary tract symptoms due to benign prostatic hyperplasia: final WATER II 5-Year clinical trial results. 2023 Journal of Urology.
3. Data on file at PROCEPT BioRobotics.
Safety and Risk Information
Risk & Safety Information: All surgical treatments have inherent and associated side effects. The most common side effects are mild and transient and may include mild pain or difficulty when urinating, discomfort in the pelvis, blood in the urine, inability to empty the bladder or a frequent and/or urgent need to urinate, and bladder or urinary tract infection. Other risks include ejaculatory dysfunction and a low risk of injury to the urethra or rectum where the devices gain access to the body for treatment. For more information about the potential side effects and risks associated with Aquablation therapy for Benign Prostatic Hyperplasia (BPH) treatment, speak with your urologist or surgeon. No claim is made that the AquaBeam Robotic System will cure any medical condition, or entirely eliminate the diseased entity. Repeated treatment or alternative therapies may sometimes be required.
Aquablation therapy is performed by urologists.
Patients should talk to their doctor to determine if Aquablation therapy is right for them. Patients and doctors should review the potential benefits and limitations of treatment together.
© 2024 PROCEPT BioRobotics Corporation.
All rights reserved. AQUABLATION, AQUABEAM, and PROCEPT BioRobotics are the registered trademarks of PROCEPT BioRobotics Corporation.
ML0575.A